Matches in SemOpenAlex for { <https://semopenalex.org/work/W2227576605> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2227576605 endingPage "e14640" @default.
- W2227576605 startingPage "e14640" @default.
- W2227576605 abstract "e14640 Background: The purpose of this prospective study is to evaluate the feasibility of chemosensitivity testing using EUS-FNA samples and determine the optimal cut-off value of gemcitabine. Methods: Thirty-two consecutive patients, who were undergone EUS-FNA in our institute between October 2006 and July 2009, with unresectable pancreatic cancer were enrolled. All patients were treated with gemcitabine. Chemosensitivity (treated/control ratio: T/C) was calculated as the percentage of quantity of ATP of a tumor treated with gemcitabine and of control. Concentration of gemcitabine was 20 μg/mL according to the peak plasma concentration. To identify the cut-off value that could predict 180 days of PFS, receiver operating characteristic (ROC) curve and corresponding area under the curve (AUC) was calculated. Results: Thirty-three times assays were performed on 32 patients. Twenty-eight patients (87.5%) were successful. Four patients of 28 patients were excluded because of impossible to keep the protocol, therefore, 24 patients could be prospectively followed. After 2 cycles chemotherapy, tumor response were PR in 2, SD in 13, and PD in 9. Response (PR) rate was 8.3%, progression arrest (PR+SD) rate was 62.5%. Median PFS was 108 days, and Median OS was 264 days. The cut-off value was determined as 74% using the ROC analysis (area under the curve = 0.727; 95% CI = 0.457-0.997). From above results, we could predict 180 days PFS with a sensitivity and specificity of 71.4% and 88.2%, respectively. When patients were divided into two groups at T/C ratio 74%, there was a significant difference between 2 groups about PFS (median: 77 vs. 205 days, p = 0.0059), on the other hand, there was no significant difference about OS. With respect to tumor response, there was no significant difference in response rate, however, there was a significant difference in progression arrest (p = 0.015). In addition, T/C ratio < 74% was only significant prognostic factor that influence PFS. Conclusions: Chemosensitivity testing usig EUS-FNA sample is feasible. According to this definition, it might be possible to select the patients who are expected favorable result by gemcitabine treatment. No significant financial relationships to disclose." @default.
- W2227576605 created "2016-06-24" @default.
- W2227576605 creator A5015613537 @default.
- W2227576605 creator A5019069276 @default.
- W2227576605 creator A5023184782 @default.
- W2227576605 creator A5036475624 @default.
- W2227576605 creator A5040773083 @default.
- W2227576605 creator A5047542052 @default.
- W2227576605 creator A5050074861 @default.
- W2227576605 creator A5052935765 @default.
- W2227576605 creator A5072673296 @default.
- W2227576605 creator A5077151260 @default.
- W2227576605 creator A5083908667 @default.
- W2227576605 date "2010-05-20" @default.
- W2227576605 modified "2023-09-25" @default.
- W2227576605 title "Chemosensitivity testing to predict chemosensitivity for gemcitabine, using the biopsy specimens obtained by EUS-FNA from unresectable pancreatic cancer." @default.
- W2227576605 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e14640" @default.
- W2227576605 hasPublicationYear "2010" @default.
- W2227576605 type Work @default.
- W2227576605 sameAs 2227576605 @default.
- W2227576605 citedByCount "0" @default.
- W2227576605 crossrefType "journal-article" @default.
- W2227576605 hasAuthorship W2227576605A5015613537 @default.
- W2227576605 hasAuthorship W2227576605A5019069276 @default.
- W2227576605 hasAuthorship W2227576605A5023184782 @default.
- W2227576605 hasAuthorship W2227576605A5036475624 @default.
- W2227576605 hasAuthorship W2227576605A5040773083 @default.
- W2227576605 hasAuthorship W2227576605A5047542052 @default.
- W2227576605 hasAuthorship W2227576605A5050074861 @default.
- W2227576605 hasAuthorship W2227576605A5052935765 @default.
- W2227576605 hasAuthorship W2227576605A5072673296 @default.
- W2227576605 hasAuthorship W2227576605A5077151260 @default.
- W2227576605 hasAuthorship W2227576605A5083908667 @default.
- W2227576605 hasConcept C121608353 @default.
- W2227576605 hasConcept C126322002 @default.
- W2227576605 hasConcept C126894567 @default.
- W2227576605 hasConcept C143998085 @default.
- W2227576605 hasConcept C188816634 @default.
- W2227576605 hasConcept C2775934546 @default.
- W2227576605 hasConcept C2776694085 @default.
- W2227576605 hasConcept C2777844706 @default.
- W2227576605 hasConcept C2778076430 @default.
- W2227576605 hasConcept C2780210213 @default.
- W2227576605 hasConcept C2780258809 @default.
- W2227576605 hasConcept C2989005 @default.
- W2227576605 hasConcept C58471807 @default.
- W2227576605 hasConcept C71924100 @default.
- W2227576605 hasConcept C76318530 @default.
- W2227576605 hasConcept C90924648 @default.
- W2227576605 hasConceptScore W2227576605C121608353 @default.
- W2227576605 hasConceptScore W2227576605C126322002 @default.
- W2227576605 hasConceptScore W2227576605C126894567 @default.
- W2227576605 hasConceptScore W2227576605C143998085 @default.
- W2227576605 hasConceptScore W2227576605C188816634 @default.
- W2227576605 hasConceptScore W2227576605C2775934546 @default.
- W2227576605 hasConceptScore W2227576605C2776694085 @default.
- W2227576605 hasConceptScore W2227576605C2777844706 @default.
- W2227576605 hasConceptScore W2227576605C2778076430 @default.
- W2227576605 hasConceptScore W2227576605C2780210213 @default.
- W2227576605 hasConceptScore W2227576605C2780258809 @default.
- W2227576605 hasConceptScore W2227576605C2989005 @default.
- W2227576605 hasConceptScore W2227576605C58471807 @default.
- W2227576605 hasConceptScore W2227576605C71924100 @default.
- W2227576605 hasConceptScore W2227576605C76318530 @default.
- W2227576605 hasConceptScore W2227576605C90924648 @default.
- W2227576605 hasIssue "15_suppl" @default.
- W2227576605 hasLocation W22275766051 @default.
- W2227576605 hasOpenAccess W2227576605 @default.
- W2227576605 hasPrimaryLocation W22275766051 @default.
- W2227576605 hasRelatedWork W114644245 @default.
- W2227576605 hasRelatedWork W2005537476 @default.
- W2227576605 hasRelatedWork W2072917208 @default.
- W2227576605 hasRelatedWork W2111373770 @default.
- W2227576605 hasRelatedWork W2165480504 @default.
- W2227576605 hasRelatedWork W2376347278 @default.
- W2227576605 hasRelatedWork W3029364823 @default.
- W2227576605 hasRelatedWork W3092528792 @default.
- W2227576605 hasRelatedWork W3192482352 @default.
- W2227576605 hasRelatedWork W4254486378 @default.
- W2227576605 hasVolume "28" @default.
- W2227576605 isParatext "false" @default.
- W2227576605 isRetracted "false" @default.
- W2227576605 magId "2227576605" @default.
- W2227576605 workType "article" @default.